Shared on 26 Jun 26
Fair value Decreased 88%TRAW: Influenza Setback Will Shift Focus Toward Broad Antiviral Pipeline Potential
1 viewusers have viewed this narrative update
Traws PharmaTRAW
Fair Value
US$1
Share price26 Jun
US$0.5446.1% undervalued intrinsic discount
1Y-63.58%
7D22.19%
COVID Antivirals And Pandemic Preparedness Will Drive Compelling Long Term Opportunity
AN
Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.
Published
07 Dec 25
Updated
26 Jun 26
Views
12
Not Invested